酪氨酸激酶抑制剂的药物相互作用研究进展

Research progress of drug interactions of tyrosine- kinase inhibitors

口服酪氨酸激酶抑制剂(TKIs)高效、低毒因而使用广泛,药物相互作用风险也随之增加。本文总结了截止至2015年12月31日,美国食品和药物管理局和我国国家食品药品监督管理总局批准用于非小细胞肺癌的TKIs与其他药物和食物的相互作用研究进展,并给出用药建议,为临床使用提供参考。

Due to its higher efficacy and safety compared with traditional chemotherapy, tyrosine-kinase inhibitors （TKIs） have been widely used in cancer patients and there is also a high potential for interactions between TKIs and other drugs. This review discussed drug interactions about FDA or CFDA-approved TKIs in non-small-cell lung cancer by Dec 31, 2015, providing some recommendations for clinical use.